Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 336 Polycystic Ovary Syndrome 37 Neoplasm Metastasis 21 Endometrial Neoplasms 21 Ovarian Neoplasms 16 Neoplasms 13 Infertility 9 Advanced Breast Cancer 9 Fallopian Tube Neoplasms 8 Recurrence 7 Carcinoma, Intraductal, Noninfiltrating 7 Carcinoma, Ductal, Breast 7 Osteoporosis 6 Carcinoma, Lobular 6 Breast Neoplasms, Male 6 Breast Diseases 6 Triple Negative Breast Neoplasms 5 Breast Carcinoma In Situ 5 Prostatic Neoplasms 4 Leiomyoma 4 Infertility, Female 4 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Arthralgia 4 Obesity 3 Neoplasms, Hormone-Dependent 3 Carcinoma, Ovarian Epithelial 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡